Category:

Regulation

Will RBI joining NGFS help in climate finance?

The 22nd Financial Stability Report (FSR22) of the RBI had, about the “climate-related risk” that the value of financial assets/liabilities could be affected either by continuation in climate change (physical risks), or by an adjustment towards a low-carbon economy (transition risks). The manifestation of physical risks could lead to a sharp fall in asset prices and increase in uncertainty, it said.

read more

Sebi board agrees in principle to ‘controlling shareholders’ concept

The board noted that the investor landscape is now changing, with private equity and institutional investors holding significant shareholding in listed companies. ”In recent years, a number of businesses and new-age companies with diversified shareholding and professional management that are coming into the listed space are non-family owned and/or do not have a distinctly identifiable promoter group,” the board said.

read more

Willis Towers mulls sale of reinsurance unit after halting merger

Reports this week suggested Gallagher was close to clinching a deal for Willis Re, but Willis Towers Watson Chief Executive Officer John Haley said he is considering wider possibilities.

“We’re conducting a review of strategic alternatives for Willis Re,” Haley told a conference call on Tuesday reporting on second-quarter results. While the timing was “appropriate” given the failed merger, he warned that a sale was not assured.

read more

Pvt hospitals, labs welcome Delhi govt’s announcement on capping of rate of RT-PCR and RATs

Welcoming the decision Dr Bhagwan Mantri, Senior Consultant, Respiratory and Chest Medicine at Moolchand Hospital said, ”RT-PCR tests are required for everything these days – for travel purposes and for hospital admissions. Capping of prices will help people in going for tests and they will not be hesitant. It will also prevent people from going in for fake test reports that are available for Rs 200-300.”

read more

ESG integration in business will help create long-term value: Report

The top five risks of the decade that can majorly impact the society include infectious diseases, climate action failure, weapons of mass destruction, biodiversity loss and natural resource crisis, the report said.

The likelihood of extreme weather, climate action failure, human environmental damage, infectious diseases and biodiversity loss becoming a reality is increasing day by day, it added.

read more

Johnson and Johnson still in discussion with Centre over indemnity issue: Sources

As per the sources, Johnson and Johnson is not going to participate in the trials for the single-dose vaccine in India. They are also having discussions over indemnity with the government.In June, a spokesperson of the company told ANI that as per the recent announcement by the Drugs Controller General of India (DCGI), there is no longer a requirement to conduct bridging clinical studies of COVID-19 vaccines in India.

read more